Thursday, 19 September 2019

Hancock Jaffe appoints new CFO

16 July 2018 | News

Bob Rankin assumes the CFO role from Bill Abbott, who will be leaving the company on July 20, 2018.

Singapore  Hancock Jaffe Laboratories, a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, announced that Bob Rankin will be joining the company as its chief financial officer beginning July 16, 2018. He assumes the CFO role from Bill Abbott, who will be leaving the company on July 20, 2018.

“Bob Rankin has many years of CFO experience with public companies, and is a welcome addition to our executive management team,” said Robert Berman, Hancock Jaffe’s CEO.  “We thank Bill Abbott for his years of service to the company and expect a smooth and seamless transition.”

Mr. Rankin has more than twenty years of relevant experience helping to shape the operations and financial health of public and private companies across multiple industries. Immediately prior to joining Hancock Jaffe, he served as Chief Financial Officer of Horsburgh & Scott, a gear manufacturing firm where he led a turnaround from an 11.6 percent loss in sales to 5.9 percent in profit. 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls